Immunotherapy combo shows promise in stomach cancer trial
NCT ID NCT05008783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether adding an immunotherapy drug called AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 610 participants received either AK104 plus chemo or a placebo plus chemo. The study is complete, and researchers are looking at overall survival and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104 (a type of immunotherapy) plus oxaliplatin and capecitabine (chemotherapy)
What this could lead to
If it works, this could offer a new first-line treatment option for people with advanced stomach or gastroesophageal junction cancer, potentially improving survival.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The added immunotherapy may cause immune-related side effects, and it may not improve survival compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100143, China
-
The First Affiliated Hospital of Zhejiang University Medical College
Hangzhou, Zhejiang, 310003, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610044, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 20032, China